January 3, 2022

The U.S. FDA has modified the emergency use authorization for Pfizer’s Comirnaty® (COVID-19 vaccine, mRNA) to expand its use.

  • The vaccine’s use as a single booster dose now extends to include individuals 12-15 years of age who received Comirnaty for their primary COVID-19 vaccination series. The FDA had previously expanded Comirnaty’s authorized use as a booster dose to ages 16 and up on December 9, 2021.
  • The time between completion of primary vaccination with Comirnaty and a booster dose is now five months, down from the previously authorized six months.
  • Certain immunocompromised children 5-11 years old can receive a third primary series dose. Previously, the third primary series dose was authorized for ages 12 and up.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More